Evidence map›Paper›PMID 28213967›Full record

ArticleStem cells translational medicine2017

Extracellular Vesicles from Bone Marrow-Derived Mesenchymal Stem Cells Improve Survival from Lethal Hepatic Failure in Mice.

Hiroaki Haga, Irene K Yan, Kenji Takahashi, Akiko Matsuda, Tushar Patel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Bone-organ axes: bidirectional crosstalk.Military Medical Research · 2024
    Review
  18. Review
  19. Review
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hiroaki HagaDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Irene K YanDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Kenji TakahashiDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Akiko MatsudaDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Tushar PatelDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Jacksonville College · USMayo Clinic in Florida · US

Funding

Extracellular non-coding RNA biomarkers of hepatocellular cancerUH3TR000884 · NCATS · MAYO CLINIC JACKSONVILLE · PI PATEL, TUSHAR · 2015 to 2017
$3.0M
Mechanisms of Survival Signaling in Biliary EpitheliaR01DK069370 · NIDDK · SCOTT AND WHITE MEMORIAL HOSPITAL · PI PATEL, TUSHAR · 2005 to 2014
$2.4M
Extracellular non-coding RNA biomarkers of hepatocellular cancerUH2TR000884 · NCATS · MAYO CLINIC JACKSONVILLE · PI PATEL, TUSHAR · 2013 to 2014
$989k
NCATS NIH HHS UH2 TR000884NCATS NIH HHS UH3 TR000884NIDDK NIH HHS R01 DK069370
6 · The paper itself

Abstract

Stem cell-based therapies have potential for treatment of liver injury by contributing to regenerative responses, through functional tissue replacement or paracrine effects. The release of extracellular vesicles (EV) from cells has been implicated in intercellular communication, and may contribute to beneficial paracrine effects of stem cell-based therapies. Therapeutic effects of bone-marrow derived mesenchymal stem cells (MSC) and vesicles released by these cells were examined in a lethal murine model of hepatic failure induced by d-galactosamine/tumor necrosis factor-α (TNF-α). Systemically administered EV derived from MSC accumulated within the injured liver following systemic administration, reduced hepatic injury, and modulated cytokine expression. Moreover, survival was dramatically increased by EV derived from either murine or human MSC. Similar results were observed with the use of cryopreserved mMSC-EV after 3 months. Y-RNA-1 was identified as a highly enriched noncoding RNA within hMSC-EV compared to cells of origin. Moreover, siRNA mediated knockdown of Y-RNA-1 reduced the protective effects of MSC-EV on TNF-α/ActD-mediated hepatocyte apoptosis in vitro. These data support a critical role for MSC-derived EV in mediating reparative responses following hepatic injury, and provide compelling evidence to support the therapeutic use of MSC-derived EV in fulminant hepatic failure. Stem Cells Translational Medicine 2017;6:1262-1272.

Indexed as

AnimalsApoptosisBone Marrow CellsDisease Models, AnimalExtracellular VesiclesLiverLiver FailureMaleMesenchymal Stem CellsMiceMice, Inbred C57BLApoptosisCytokinesExtracellular vesiclesFulminant hepatic failureTumor necrosis factor

Identifiers

PMID28213967
PMCPMC5442843
OpenAlexW2588997498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.